First Day of ASH 2024- Busy Times in Leukemia Research!

Today is the beginning of the 66th annual American Society of Hematology (ASH) conferences, where specialists from all over the world get together to discuss exciting updates, research results, treatment advances, and interesting cases from their practice. 

At HealthTree Foundation, we are excited to cover sessions and new studies in future articles and make them useful and comprehensive for you. Some of them even include detailed, easy-to-understand interviews with the authors. So stay tuned to our News site as we continue to cover this important information. 

Here are relevant leukemia-centered sessions from this morning, afternoon, and evening to keep your eyes on.

Morning and Afternoon Session: Chronic Lymphocytic Leukemia

Addressing Current Questions and Controversies in the Management of CLL – What Clinicians Want to Know  

This session will focus on how specialists treat chronic lymphocytic leukemia (CLL). The faculty members will discuss the answers to questions such as: 

• What are the latest relevant research findings for CLL? 

• The results of evidence-based treatment approaches 

• What are health professional’s perspectives on ongoing studies?

In an upcoming article, we’ll cover the highlights of this session. 

An Interactive Case-based Review of CLL: Experts Explore the Latest Evidence and Guideline Updates

Recent advancements in CLL include new treatment strategies, targeted therapies, and updated clinical guidelines. In this session, we’ll cover the most recent NCCN Guideline updates and innovative clinical approaches and highlight the most relevant discussions, expert recommendations, and comprehensive clinical data. 

Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-base Platforms

In this session, CLL experts will discuss practical insights into addressing key challenges in CLL treatment, from new therapies and strategies for relapsed/refractory CLL. The topics will include: 

• Personalized selection of first-line continuous BTK inhibitors 

• Experience with BTKi-BCL2i combinations

• Therapy involving non-covalent BTKi (ncBTKi) and CAR-T immunotherapy in relapsed or refractory CLL

• Cutting-edge approaches such as next-gen BCL2 inhibitors, BTK degraders, BTKi, and bispecific antibodies for patients with multiple prior therapies.

Late Afternoon Session: Acute Myeloid Leukemia and Acute Lymphocytic Leukemia 

Addressing Current Questions and Controversies in AML Management - What Clinicians Want to Know

During this session centered on acute myeloid leukemia (AML), the areas of greatest interest from a survey completed by 50 general medical oncologists/hematologists, will be presented. This will include topics such as: 

• Relevant research findings

• The results of evidence-based treatment approaches 

• What do health professionals want to know about AML?

Stay tuned so you know all the details of this session. 

Medical Crossfire®: New Horizons in ALL—How The Experts Apply New Evidence From Adolescent & Young Adult to Adult Scenarios  

This Medical Crossfire® session addresses the challenges health professionals face in keeping up with rapid advancements in acute lymphoblastic leukemia (ALL) care. Through case-based discussions, we will inform you about the discussion of practical strategies doctors use for integrating new therapies, how they overcome barriers to their implementation, and how they manage common side effects. We will also highlight details on recent evidence and real-world practices and how healthcare professionals align patient care approaches with expert insights.

Stay Tuned! 

We’re excited to cover this important information for you so it’s comprehensive and so that you can stay updated on what can affect and benefit your life. Bookmark the link below to catch up on news about HealthTree’s conference coverage at ASH24. 

HealthTree Conference Coverage